Nomogram for Breast Cancer Brain Metastasis
A nomogram for breast cancer brain metastasis estimates an individual patient’s risk of developing brain metastases using key clinical and tumor characteristics.
Indications for Use
Used in patients with metastatic breast cancer without existing brain involvement to estimate individualized risk of developing brain metastases and guide selection for intensified surveillance or prevention‑trial enrollment. Based on validated clinical predictors (age, receptor status, metastatic burden, disease‑free interval) with moderate discrimination (AUC ~0.68–0.74) 1 [Level II evidence]. Helps enrich high‑risk cohorts and inform counseling; not for diagnostic decision making or treatment selection.
Insights & Cautions
Uses clinicopathologic factors (age, subtype, metastatic burden, disease‑free interval) to estimate individual brain‑metastasis risk. Insights: strongest predictors include ER/HER2 negativity and multiple metastatic sites 1; HER2+ and TN subtypes show highest cumulative incidence 2. Cautions: models are retrospective, modest discrimination (AUC ~0.68–0.74), risk of overestimation in modern HER2‑targeted era, and not validated for screening or altering surveillance.